Doxacor

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Doxacor

Property Description
Active ingredient Doxazosin (as mesylate salt)
Form Oral tablet (Immediate-release and Extended-release)
Pharmacological class Alpha-1-adrenergic antagonist (Alpha-1 blocker)
General purpose Management of high blood pressure and improvement of urine flow
Origin Synthetic compound (Quinazoline derivative)

What Kind of Drug is Doxacor?

Doxacor is a trade name for a prescription-only medicine (POM) whose active ingredient is Doxazosin, a synthetic compound used for its effects on blood pressure and the urinary tract. It is classified as an Alpha-1-adrenergic antagonist (or alpha-1 blocker), which means its primary role is to selectively interfere with signals that cause muscle constriction in certain parts of the body. Doxazosin is chemically identified as a Quinazoline derivative and functions as both an antihypertensive agent and a urological agent.

Doxazosin is used for both the treatment of hypertension and symptomatic benign prostatic hyperplasia (BPH). This involves managing these two conditions by targeting the same underlying receptors.


Composition and Pharmaceutical Form

Doxacor is a single active ingredient product designed for oral administration, primarily available in the tablet dosage form. The tablets contain the active agent, Doxazosin mesylate, combined with various solid excipients that form the tablet structure. Doxazosin has the ability to produce a sustained blood pressure lowering effect, which assists in maintaining blood pressure levels.

The medication is manufactured in two principal variations: an immediate-release form, where the full dose is available quickly, and an extended-release form, which controls the drug's delivery rate over a sustained period. This difference in pharmaceutical form impacts how the therapeutic effect is maintained throughout the day, offering an option for patients seeking consistent relief from hypertension or BPH symptoms.

What side effects are possible with Doxacor?

Possible Side Effects and Safety Information

The safety profile for Doxazosin (Doxacor) is structured around the physiological effects inherent to its classification as an alpha-1 blocker. Official regulatory documents categorize possible adverse reactions primarily based on incidence observed during clinical use and post-marketing surveillance.

Adverse reactions are grouped by frequency and the System-Organ Class affected. Common adverse reactions, affecting up to 1 in 10 individuals, frequently involve the Nervous System (such as dizziness, headache, and somnolence) and the Cardiovascular System (including postural dizziness). General disorders like fatigue and asthenia (physical weakness) are also classified as common.

Serious adverse reactions documented in regulatory sources include Syncope (fainting), which is a key safety concern related to sudden blood pressure changes, and the very rare event of Priapism (a persistent, painful erection). Orthostatic effects, such as postural dizziness and syncope, are explicitly noted as being more likely to occur at the start of treatment or following a dose increase.

Safety limitations and constraints are defined in the labeling. Doxazosin is officially contraindicated in patients with a history of orthostatic hypotension and those with severe hepatic impairment. Furthermore, the official label documents a risk of Intraoperative Floppy Iris Syndrome (IFIS) for patients who are currently taking or have previously taken Doxazosin and undergo cataract surgery.

Overdose and Emergency Response

Doxacor Overdose and When to Seek Help

Overexposure to Doxacor (Doxazosin) can lead to an exaggerated pharmacological effect, primarily resulting in hypotension (severely low blood pressure). This is the most frequently documented manifestation of overdosage, stemming from the drug's action as an alpha-1-adrenergic antagonist.

Documented Manifestations and Severe Outcomes

The official labeling notes that initial clinical manifestations may include dizziness, lightheadedness, and somnolence (drowsiness). The most severe documented outcomes are linked to the acute drop in blood pressure and include profound hypotension, syncope (fainting or loss of consciousness), and the potential for a seizure. Changes in heart rate, such as reflex tachycardia, may also occur. Due to high protein binding, dialysis is not expected to be beneficial for Doxazosin overexposure.

Required Emergency Actions and Supportive Management

Regulatory guidance explicitly mandates that immediate medical attention must be sought if overexposure is suspected. Contacting a poison control center or emergency services is required when the affected individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. Management procedures are strictly symptomatic and supportive, as no specific antidote is known. These procedures include placing the individual in a supine position with the legs elevated and maintaining close monitoring of vital signs.

Therapeutic Uses of Doxacor

What Doxacor Treats: Main Uses and Benefits

Doxacor is commonly used across conditions characterized by periods of heightened symptoms. It is applicable within clinical settings that involve acute or disruptive symptom patterns, where the medication serves as a component of symptomatic management. Use of the medicine is associated with managing symptoms linked to acute or episodic changes and organ-specific functional stress.


Easing Symptomatic Discomfort and Instability

The medication is commonly used when symptoms related to physical discomfort or systemic imbalance become momentarily overwhelming. It is relevant for managing symptom clusters that interfere with daily comfort, offering symptomatic relief that helps patients cope more steadily with difficult episodes. Doxacor is often applied during phases where the patient experiences heightened discomfort, helping to provide temporary assistance in symptom stabilization.

Quick Fact: Support for Functional Stability


Supporting Comfort and Stability

Doxacor is relevant in conditions characterized by episodic or fluctuating manifestations and assists with managing symptoms related to heightened physiological activity. It provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms. The medication may assist with maintaining functional stability when symptoms are more noticeable, supporting general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus overview of Doxazosin

Eligibility and Restrictions for Use

Who can and cannot use Doxacor?

This section describes the population-eligibility and non-eligibility rules for Doxacor (Doxazosin) as defined by official government regulatory documents.

Populations for Whom Use is Contraindicated

The medicine is contraindicated (must not be used) in patients with:

  • Known hypersensitivity to doxazosin, other quinazoline derivatives (e.g., prazosin, terazosin), or any excipients.
  • A history of orthostatic hypotension.
  • Overflow bladder, anuria, or progressive renal insufficiency when Doxacor is used alone for Benign Prostatic Hyperplasia (BPH).
  • Gastrointestinal obstruction or severe narrowing (for the extended-release formulation only).
  • Lactation/Breastfeeding (contraindicated in some regions).

Age-Related and Condition-Specific Eligibility

Age Group or Condition Regulatory Status
Adults (18+ years) Approved for use under labeled conditions.
Pediatric Patients (<18) Not recommended; safety and effectiveness not established.
Severe Hepatic Impairment Not recommended due to lack of clinical experience.
Renal Impairment Usual adult dosage may be used, as pharmacokinetics are generally unchanged.

Eligibility-Related Restrictions

Use requires special caution in patients with mild to moderate hepatic impairment or specific acute cardiac conditions. Additionally, carcinoma of the prostate must be ruled out before beginning treatment for BPH symptoms. Women who are pregnant should not use Doxacor unless clearly needed, as adequate human data are lacking. Patients planning cataract surgery must inform their surgeon of past or current use due to risk of Intraoperative Floppy Iris Syndrome.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define Doxacor's (Doxazosin) interaction profile primarily through pharmacodynamic effects and metabolic pathways. Co-administration with other quinazoline derivatives is formally restricted due to the documented risk of cross-hypersensitivity.

Pharmacodynamic and Metabolic Interactions

Interaction Entity Official Outcome (Regulatory Statement)
Phosphodiesterase-5 (PDE-5) Inhibitors (e.g., Sildenafil, Tadalafil) Risk of additive blood pressure lowering effects resulting in symptomatic hypotension.
Other Antihypertensive Drugs Potential for enhanced hypotensive effect.
Strong CYP 3A4 Inhibitors (e.g., Ketoconazole, Ritonavir) May increase systemic exposure to Doxazosin, as the drug is metabolized by CYP 3A4.

Co-administration of the PDE-5 inhibitor requires a specific procedural constraint: the inhibitor therapy should be initiated at the lowest dose to manage the interaction risk.

Exposure and Population Notes

The substance Cimetidine is documented to increase Doxazosin's mean overall exposure (AUC) by ten percent. Concerning population-specific constraints, Doxazosin use is not recommended in patients with severe hepatic impairment due to a lack of clinical experience regarding drug clearance. Additionally, co-administration with alcohol may increase the blood pressure-lowering effect.

Mechanism of Action

The mechanism of Doxazosin involves selective Alpha-1 Adrenergic Receptor (alpha1-AR) antagonism (or blockade). By occupying these receptors, it prevents the action of the neurotransmitter Norepinephrine, which normally triggers smooth muscle contraction. This action produces two distinct, system-level physiological effects across different organ systems.


Modulating Systemic Vascular Tone

This domain covers the interaction with alpha1-ARs on the muscular walls of blood vessels. The blockade of vascular alpha1-ARs inhibits the signal for intracellular calcium mobilization, preventing sustained contraction and promoting systemic vasodilation. This physiological consequence results in a state characterized by reduced Total Peripheral Resistance throughout the circulatory system.


Relaxation of Lower Urinary Tract Smooth Muscle

This domain addresses the selective action on alpha1A-receptors found in the prostate capsule and bladder neck. Antagonism in this area halts the sympathetic signaling that maintains resting muscle tension in the urinary outflow tract. The resulting relaxation of this smooth muscle tissue mechanically reduces urethral resistance.

Dosage and Administration Information

How to Use Doxacor

Doxacor, whose active ingredient is Doxazosin, is a prescription-only medicine used strictly via the oral route as tablets. Its administration is structured by established protocols that define the starting dose and the slow adjustment process required to reach a maintenance dose. This medication is taken once daily.


Official Administration Protocols

Feature General Administration
Dosing Initiation Treatment begins with a low initial dose of 1 mg once daily for immediate-release (IR) tablets.
Dose Titration The dose is gradually increased by doubling the amount at 1 to 2-week intervals until a stable maintenance dose is achieved.
Maximum Dose The maximum daily dose for the IR form is 16 mg for hypertension and 8 mg for symptomatic BPH.

Form-Specific Instructions

Doxazosin is available in both immediate-release and extended-release (ER) forms, each with specific instructions for intake. The immediate-release tablets can be taken with or without food. In contrast, the extended-release tablets should be taken with breakfast to ensure consistent drug delivery.

Crucially, the extended-release tablet must be swallowed whole and must not be crushed, split, or chewed. Breaking the ER tablet compromises its sustained-release mechanism, which is designed to deliver the drug slowly over time. If administration is interrupted for several days, the standard procedure is to restart treatment at the initial low dose and repeat the slow titration process.

Special Population Rules

For patients with renal (kidney) impairment, it is generally indicated that no initial dose adjustment is required. However, caution and careful monitoring are necessary when administering Doxazosin to patients with hepatic (liver) impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Summary of Research Findings

Studies have been conducted to explore the compound's characteristics and how it is processed by the body. Studies have investigated whether the drug is associated with changes in quality of life in participants with the condition.


Key Clinical Trials

Efficacy and Symptom Changes

Large-scale randomized controlled trials (RCTs) have been conducted to evaluate the drug. Research examined the time to symptom change, with findings reporting changes within a specific timeframe in a reported percentage of participants. The studies also investigated whether participants experienced symptom changes over time. Studies evaluated various doses across different study populations to characterize the response.

Tolerability and Reported Adverse Events

Trials have consistently examined the drug’s tolerability. Common reported side effects included fatigue and mild gastrointestinal changes. Study reports noted that these were typically temporary. Studies investigating individuals with existing heart conditions have been conducted to evaluate potential associations with side effects.


Combination Therapy Studies

Research has characterized the drug's properties. Some studies have investigated whether combined interventions, including lifestyle changes, are associated with different outcomes. Research has examined whether the combination is associated with differences in long-term prognosis.


Conclusion on Evidence

Research continues to investigate the drug's full profile. Overall, the body of research has explored the drug’s potential impact. Individuals may wish to discuss the findings with a healthcare provider. Research has investigated the tolerability and reported adverse events during long-term administration in study populations.

Frequently Asked Questions (FAQ)

Common questions about Doxacor (FAQ)

Q: How quickly do people usually start to notice an effect from Doxacor?

A: Studies indicate that the effect of Doxacor varies depending on the condition being treated. When used for high blood pressure, the maximum reduction in blood pressure typically occurs a few hours after taking the medicine. For the symptomatic treatment of BPH (enlarged prostate), an improvement in urinary flow rate may be seen within the first one to two weeks of treatment.

Q: Is Doxacor considered a long-term or short-term treatment?

A: Official information indicates that Doxacor is generally intended for long-term use in managing chronic conditions such as high blood pressure and BPH. Regulatory documents indicate that Doxacor is typically prescribed for consistent, long-term administration to manage chronic conditions.

Q: Are there any specific foods or drinks that should be avoided while using Doxacor?

A: Regulatory documents state that Doxacor should be used cautiously with alcohol, as co-administration may increase the medicine’s blood pressure-lowering effect. Grapefruit juice is known to inhibit the CYP3A4 enzyme, which metabolizes the drug. Regulatory documents note that strong inhibitors of this enzyme may increase Doxacor’s concentration in the body, potentially enhancing its blood pressure-lowering effect.

Q: Is Doxacor known to interact with herbal supplements like St. John's Wort?

A: Official regulatory documents indicate that Doxacor interacts with strong inhibitors of the CYP3A4 enzyme. This is the pathway the body uses to process the medicine. Because certain supplements, such as St. John’s Wort, may affect this enzyme, this interaction profile is relevant to their co-administration.

Q: If I miss a dose of Doxacor, what is the usual procedure?

A: Official product information contains guidance for managing a missed single daily dose, including when to skip a missed dose and continue the regular schedule. The guidance for interrupted administration (missing multiple doses) often requires the patient to repeat the initial slow dose titration process.

Q: Can Doxacor affect my ability to drive or operate machinery?

A: Official regulatory information notes that common side effects, such as dizziness and fatigue, can impair the ability to perform activities requiring mental alertness, such as driving or operating machinery. This is particularly relevant when initiating treatment or increasing the dose.

Q: What are the general expectations for a person taking Doxacor?

A: The drug's official purpose is the management of high blood pressure and the improvement of BPH symptoms. Research evidence indicates that these effects are managed through sustained daily use, consistent with the medicine's approved indications.

Q: Can Doxacor be used by women who are planning to become pregnant?

A: The official documentation confirms that there is no evidence suggesting Doxacor impairs fertility. However, information regarding use during pregnancy exists, making a review of medication use relevant when a person is planning to conceive.

Q: Does Doxacor's effectiveness change over time?

A: Official clinical trials for Doxacor have evaluated both the effectiveness and tolerability of the drug during long-term administration. The drug’s inherent properties allow for once-daily dosing, which is intended to maintain a consistent therapeutic effect over time.

Q: Can Doxacor worsen or trigger other health conditions?

A: Regulatory documents list specific situations where the medicine is contraindicated (should not be used). These include a history of orthostatic hypotension or severe liver impairment. The official label documents a risk of Intraoperative Floppy Iris Syndrome (IFIS) for patients who are currently taking or have previously taken Doxacor and plan to undergo cataract surgery. Patients are required to inform their surgeon of this use.

Q: Is the research evidence for Doxacor considered strong by regulatory bodies?

A: Regulatory approval for Doxacor is based on evidence derived from controlled clinical trials. These studies, which follow rigorous standards, demonstrated the drug's efficacy and tolerability for its approved uses in reducing blood pressure and improving BPH symptoms.

Q: Is it necessary to take Doxacor at the exact same time every day?

A: Official information indicates that taking the once-daily dose around the same time each day helps to maintain consistent medicine levels in the body.

Q: Is Doxacor meant to cure a condition or just manage symptoms?

A: According to the official product information, Doxacor is indicated for the management (treatment) of high blood pressure and the improvement of symptoms related to BPH. It is not described as a cure for either condition.

Q: Does Doxacor have any known issues when taken with common pain relievers?

A: Official interaction databases indicate no known major interaction between Doxacor and common nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. The safety of co-administration is routinely assessed by healthcare providers.

Q: Is Doxacor suitable for older adults (seniors)?

A: Official information indicates Doxacor is approved for use in adults, including older individuals. Careful monitoring of kidney and liver function is considered relevant when administered to this population.

Q: Is there a possibility Doxacor could cause weight gain?

A: Official regulatory safety reports classify weight gain as an uncommon adverse event, meaning it has been reported to affect less than 1% of individuals in clinical trials.

Q: What are the most common reasons a patient might stop taking Doxacor?

A: Based on clinical study reports, the most frequent reasons leading to the discontinuation of Doxacor were related to central nervous system effects. These commonly included dizziness and somnolence (sleepiness).

Q: Does Doxacor contain gluten, lactose, or other common allergens?

A: The official product labeling (DailyMed) lists all the excipients (non-active components) used to form the tablet. This information can be used to check against specific allergen concerns such as gluten or lactose.

Q: Is Doxacor a controlled substance?

A: Doxacor (Doxazosin) is classified as a prescription-only medicine (POM). However, it is not listed or scheduled as a controlled medication by the US Drug Enforcement Administration (DEA) or other major regulatory bodies.

Q: What should I do if a side effect of Doxacor doesn't go away?

A: Official patient information describes that persistent or severe side effects require a review by a healthcare provider. Serious reactions, such as fainting (syncope), require immediate medical attention.

Q: Does Doxacor interact with birth control pills?

A: Regulatory guidance confirms that Doxacor (Doxazosin) is not known to affect the functionality or effectiveness of hormonal contraception, such as birth control pills.

Q: Are there any specific lab tests needed while taking Doxacor?

A: Official documentation requires that doctors rule out prostate carcinoma (cancer) before starting treatment for BPH symptoms. While official guidance does not typically mandate routine blood counts or liver function tests for Doxacor alone, clinical monitoring may be required based on the individual's health status.

Q: Why is Doxacor sometimes described as a 'first-line' or 'second-line' treatment?

A: The positioning of Doxacor (an alpha blocker) in treatment guidelines varies depending on the specific condition and the individual patient’s characteristics. Official patient resources often state that for high blood pressure, it may not be the first treatment option but plays an important role based on the patient’s age, coexisting conditions, and combination therapy needs.

Q: Is Doxacor available as a generic version?

A: Yes, regulatory records (such as the FDA Orange Book) confirm that generic versions of the immediate-release tablet form of Doxazosin are approved and available.

Q: Can Doxacor cause hair loss?

A: Alopecia, or hair loss/thinning, is listed as a reported adverse event in official regulatory safety documents. It is considered a rare side effect.

Q: How long does Doxacor stays in the body after the last dose?

A: Pharmacological information states that Doxacor has a long terminal elimination half-life of approximately 22 hours. This means that it takes about 22 hours for half of the medicine to be cleared from the bloodstream.

Q: Does Doxacor interact with common over-the-counter allergy medications?

A: Some common over-the-counter allergy medicines (antihistamines) can cause additive effects that may increase drowsiness and dizziness or enhance the blood pressure-lowering effect when combined with Doxacor. The co-administration of Doxacor with these medications is a relevant factor for a healthcare provider to consider during assessment.

Q: Are there any known issues with Doxacor and grapefruit juice?

A: Grapefruit juice is known to strongly inhibit the CYP3A4 enzyme, which is responsible for breaking down Doxacor in the body. Official interaction studies suggest that consuming grapefruit juice may increase the concentration of Doxacor in the blood, potentially leading to increased blood pressure lowering effects.

Q: Can Doxacor cause mood swings or changes in behavior?

A: Official regulatory safety reports list psychiatric adverse reactions, such as anxiety, depression, agitation, nervousness, and insomnia, as uncommon side effects. These effects have been reported in less than 1% of patients in clinical trials.

Q: Are there restrictions on physical activity while using Doxacor?

A: Official warnings relate to the risk of dizziness or fainting (syncope) when starting the medication or increasing the dose. This risk is relevant during physical activities where low blood pressure (hypotension) or dizziness could be hazardous.

How should Doxacor be stored and disposed of?

The storage and disposal of Doxacor tablets must strictly follow official regulatory requirements to maintain product quality and safety.

Official Storage and Handling

Requirement Official Regulatory Statement
Temperature Store at room temperature, generally between 68°F and 77°F (20°C and 25°C).
Protection Keep away from excess heat and moisture (e.g., do not store in the bathroom).
Container Keep the medication in the original container, ensuring it is tightly closed to protect the contents.
Child Safety Must be kept out of the sight and reach of children. Use a locked safety cap and store in a secure, elevated location.

Official Disposal Instructions

Expired or unused Doxacor must not be disposed of in household waste or flushed down a toilet unless specific local instructions advise otherwise. Instead, the product must be discarded according to local requirements. This often involves returning the medication to a pharmacist or using a community-based drug take-back program for regulated disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Doxacor found in:

A-Z Index: